SMMGP/ FDAP is delighted to have been accepted as a member of the Alcohol Health Alliance (AHA). In doing so we join a coalition of 50 organisations working together to promote evidence-based policies to reduce the harm caused by alcohol. Members include medical royal colleges, charities, patient representatives and alcohol health campaigners.
 
Kate Halliday, Executive Director of SMMGP and FDAP says: ‘We are excited to be accepted as a member of AHA. SMMGP/ FDAP is keen to reduce the harm that alcohol cause in society and as a member of AHA we are joining a strong group of non-governmental organisations calling for evidence-based approaches including better labelling on alcohol products, and minimum unit pricing. This will make our campaigning on alcohol so much more effective.’

Professor Sir Ian Gilmore, Chair of the Alcohol Health Alliance UK, said: "We are delighted to welcome SSMGP/ FDAP as a member to the Alcohol Health Alliance UK. Alcohol harm costs this country between £21-£52 billion annually and is the biggest risk factor for death, ill-health and disability among 15-49 year-olds. The role of primary care is vital, and by working together with members such as SSMGP/ FDAP, the Alcohol Health Alliance UK aims to tackle alcohol harm and build a healthier society."

To keep updated with AHA activities, sign up here.

For any questions or comments please contact FDAP.

News

SMMGP/FDAP educational accreditation

SMMGP/ FDAP are pleased to launch a new service providing educational accreditation for courses and educational activities related to the addictions field to provide a quality mark for providers. Accredited courses go through a process of assessment overseen by SMMGP Clinical Director and the FDAP Assessment Board in order to pass robust educational standards. Please visit our website for more information.

SMMGP medicinal cannabis sponsored clinical update

This sponsored clinical update focuses on the emerging evidence base for medicinal cannabis for a range of indications. 

The first half of the update will look at medicinal cannabis for the treatment of cannabis dependence and withdrawal. The second half focuses on medicinal cannabis for the treatment of chronic non-cancer pain (CNCP), and post-traumatic stress disorder (PTSD).

This clinical update is supported by an unrestricted education grant from Althea MMJ UK Ltd., a licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis. Althea MMJ UK Ltd has had no input into the content of the clinical update. Editorial rights belong to the author, Thomas Jones, on behalf of SMMGP/FDAP.

Read Clinical Update

Watch again

Covid-19 and drug and alcohol services: we are through the rescue phase, what's next?

Drug and alcohol services and their clients have experienced massive change in the delivery of treatment over the past few weeks in response to the pandemic. This webinar looks at the next steps, as services navigate the relaxation of some of the lockdown measures. Watch the webinar

Last chance to register for the Essentials Webinar Series | Lockdown and alcohol: the role of primary care

Essentials Webinar Series is a programme of 1.5-hour webinars by RCGP – broadcast live – providing expert specialist clinical training and essential information. These webinars are recorded live and are available for delegates to access freely for six months from the webinar date. 

Date: Wednesday 29 July 2020
Time: 19:00 - 20:30